Literature DB >> 1966939

Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin.

M S Islam1, W H Stimson.   

Abstract

Four monoclonal antibodies (T2D1, T3B1, T7B2 and T4C4) were produced and characterized against Sh. dysenteriae type 1. These monoclonal antibodies (McAbs) were shown to be directed against the same or adjacent determinants on the A-subunit of the Shiga toxin. All the anti-Shiga toxin McAbs are IgG1 (kappa) antibodies and have the capacity to neutralize the cytotoxic and neurotoxic effects of the Shiga toxin: the data strongly suggest that both of the activities, associated with the toxin, are due to the same molecule. In addition, the McAbs were found to be highly protective, at low dose, when administered therapeutically to lethally-treated animals.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1966939

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN： 0141-2760


  13 in total

1.  A monoclonal antibody to an abrin chimera recognizing a unique epitope on abrin A chain confers protection from abrin-induced lethality.

Authors:  Meenakshi Sundaram Kumar; Anjali A Karande
Journal:  Hum Vaccin Immunother       Date:  2015-09-17       Impact factor: 3.452

2.  Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.

Authors:  Abhineet S Sheoran; Susan Chapman-Bonofiglio; Barrett R Harvey; Jean Mukherjee; George Georgiou; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells.

Authors:  D E Akiyoshi; C M Rich; S O'Sullivan-Murphy; L Richard; J Dilo; A Donohue-Rolfe; A S Sheoran; S Chapman-Bonofiglio; S Tzipori
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

4.  A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model.

Authors:  Leticia V Bentancor; Marcos Bilen; Romina J Fernández Brando; María Victoria Ramos; Luis C S Ferreira; Pablo D Ghiringhelli; Marina S Palermo
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

Review 5.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Production and characterization of protective human antibodies against Shiga toxin 1.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 7.  Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection.

Authors:  Nathan K Ho; Aleah C Henry; Kathene Johnson-Henry; Philip M Sherman
Journal:  Can J Gastroenterol       Date:  2013       Impact factor: 3.522

8.  Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants.

Authors:  Abhineet S Sheoran; Susan Chapman; Pradeep Singh; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

9.  Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine.

Authors:  B T Bosworth; J E Samuel; H W Moon; A D O'Brien; V M Gordon; S C Whipp
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

10.  Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS).

Authors:  Paul N Goldwater; Karl A Bettelheim
Journal:  BMC Med       Date:  2012-02-02       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.